Caddis is in the business of making antibiotics. We
use a combination of whole cell- and target-based-
screening approaches to develop small molecule
inhibitors of enzymes that are required for bacterial
nucleic acid metabolism and survival (essential).
Compounds that have been identified via these efforts
are expected to be deleterious to bacteria and mitigate
infection. We have identified/are developing agents
that erradicate S. aureus and A. baumannii.
| Services |
 |
| |
 |
| |
 |
Research
S. aureus and A. baumannii are particularly deadly
organisms. "Staph" causes at least 90,000
infections and 19,000 deaths annually in the US. A.
baumannii is a "silent killer" of injured military
personnel. Both organisms have developed
resistance to all currently available antibiotics. Thus,
new antimicrobials are urgently needed for the
treatment of S. aureus and A. baumannii infections.
organisms. "Staph" causes at least 90,000
infections and 19,000 deaths annually in the US. A.
baumannii is a "silent killer" of injured military
personnel. Both organisms have developed
resistance to all currently available antibiotics. Thus,
new antimicrobials are urgently needed for the
treatment of S. aureus and A. baumannii infections.
Our drug discovery results have been highlighted at
regional, national, and international meetings
including:
regional, national, and international meetings
including:
 | Staphylococcal Diseases Gordon Conference (2007 | |
| Les Diablerets, Switzerland) |
| Interscience Conference on Antimicrobial Agents and | |
| Chemotherapy (2007 Chicago, IL) |
| New Mexico State (2008 Las Cruces, NM) | |